ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Prognostic Stratification in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line Androgen Receptor Pathway Inhibitor-Based Combination Therapy.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to stratify clinical risk among patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) treated with first-line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).
methodsWe retrospectively analyzed 626 patients with high-volume mHSPC treated with ARPI+ADT between November 2016 and April 2025. A multivariable Cox model for time to castration-resistant prostate cancer (TTCRPC) was developed using nine baseline characteristics, including age, hemoglobin, ECOG performance status, clinical T stage, ISUP grade group, EOD score, lung and liver metastases, and LDH, selected based on clinical relevance and prior evidence. Model discrimination and calibration were assessed using bootstrap internal validation. Patients were stratified into three risk groups based on the linear predictor, and associations with TTCRPC and overall survival (OS) were evaluated.
resultsThe median follow-up was 34.8 months. Clinical T4 stage, ISUP grade group 5, and higher LDH were independently associated with shorter TTCRPC, whereas lung metastasis was associated with longer TTCRPC. The model had an optimism-corrected C-index of 0.69. TTCRPC differed significantly across the low-, intermediate-, and high-risk groups (p < 0.001); compared with the low-risk group, the HRs were 1.48 (95% CI 1.00-2.17) for the intermediate-risk group and 4.09 (95% CI 2.90-5.77) for the high-risk group. OS also differed significantly across the three risk groups (p < 0.001).
conclusionsIn patients with high-volume mHSPC treated with ARPI+ADT, the model showed modest discrimination for TTCRPC and identified groups with different TTCRPC and OS outcomes. These findings suggest the presence of clinically heterogeneous subgroups within high-volume mHSPC and warrant independent validation in external cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.